![Open Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextgreen.png)
![Restricted Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextred.png)
![Open Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextgreen.png)
![Open Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltext_open_medium.gif)
![Restricted Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextred.png)
![Restricted Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltext_restricted_medium.gif)
Introduction of Probiotic Type of Yogurt for the Treatment of Dysbiosis of Patients with Lymphogranulomatosis Under Polychemotherapy by BEACOPP‑II Protocol
Subscribe/Renew Journal
The efficacy of using probiotic preparations of the yogurt type was studied in 136 patients with lymphogranulomatosis, suffering from intestinal dysbiosis while taking antibiotic therapy and polychemotherapy (BEACOPP‑II protocol). It was found that probiotics of this type are highly effective for the treatment of dysbiotic disorders of the intestines in cancer and hematological patients. Their use significantly reduces the risk of complications such as an unpleasant aftertaste in the mouth, belching, heartburn, diarrhea, constipation, flatulence, discomfort or periodic abdominal pain. It is recommended that prolonged therapy with a probiotic of the yogurt type be used in these groups of patients.
Keywords
Probiotic, dysbiosis, eubiosis, dyspepsia, lymphogranulomatosis, polychemotherapy.
Subscription
Login to verify subscription
User
Font Size
Information
![](https://i-scholar.in/public/site/images/abstractview.png)
Abstract Views: 738
![](https://i-scholar.in/public/site/images/pdfview.png)
PDF Views: 0